Pharmacotherapy quality and patient safety in haemodialysis patients treated with erythropoiesis-stimulating agents

Abstract Objective To assess an interdisciplinary programme for the improvement of pharmacotherapy quality and patient safety in patients with chronic renal disease who are treated with erythropoiesisstimulating agents. Method Observational, longitudinal study. Retrospective analysis (period A) and prospective analysis (period B) following implementation of the programme for haemoglobin values and monthly erythropoiesisstimulating agent dosage. The proportion of patients with haemoglobin values within the target range (10-5-12.5 g/dL) and those with values above the safety limit (≥12.5 g/dL) were compared every 4 months and the average percentage of time with haemoglobin values within the t…